The Foundation Dedicated to Discovering a Cure for Neuroendocrine Cancer

Caring for Carcinoid Foundation

Clinical Trials Finder

Syndicate content

The Caring for Carcinoid Foundation offers its Clinical Trials Finder and Patient Resource. This resource will provide the neuroendocrine tumor community with the most up-to-date and comprehensive information on relevant clinical trials in the United States.

With this resource, patients and caregivers may learn about the availability and purpose of existing clinical trials, and access supplemental resources from the Food and Drug Administration, the American Cancer Society and the National Cancer Institute.

By using CFCF's Clinical Trials Finder, patients and caregivers can search our comprehensive neuroendocrine tumor database of clinical trials, which consists of all active clinical trials being conducted in the US for carcinoid, pancreatic neuroendocrine tumors and pheochromocytoma.

Visit our About Clinical Trials page to learn more. For additional information on clinical trials or help using this site, please contact CFCF at 617-948-2514 or info@caringforcarcinoid.org.

Titlesort icon Phase Status Conditions State
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction I Enrolling Neuroendocrine Tumor
CA
GA
MD
MA
MI
NY
OH
PA
WI
Treatment of Patients With Hepatic Neuroendocrine Metastases Using Drug-Eluting Bead Embolization Enrolling Neuroendocrine Tumor MD
Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy Enrolling Neuroendocrine Tumor IL
Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery I/II Enrolling Pancreatic Neuroendocrine Tumor
IL
MI
PA
TN
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma I/II Enrolling
Carcinoid Tumor
Neuroendocrine Tumor
CA
FL
MN
MO
NJ
NY
TN
TX
Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy II Not Recruiting
Carcinoid Tumor
Neuroendocrine Tumor
AK
CA
FL
IN
IA
MA
NE
TX
Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours (CLARINET) III Not Recruiting
Neuroendocrine Tumor
Pancreatic Neuroendocrine Tumor
CA
IA
MD
NY
OR
TX
WI
Study of Capecitabine and Temozolomide for Progressive, Differentiated, Metastatic Neuroendocrine Cancers II Not Recruiting Neuroendocrine Tumor NY
Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors I Not Recruiting
Carcinoid Tumor
Neuroendocrine Tumor
Pancreatic Neuroendocrine Tumor
MA
Safety Study of MGA271 in Refractory Cance I Enrolling Pulmonary Carcinoid
PA
TN
Safety Profile Assessment of TheraSphere® Yttrium-90 Glass Microspheres Used for Treatment of Metastatic Liver Disease From Primary Colorectal, Neuroendocrine, Cholangiocarcinoma, Melanoma, and Breast Cancers Refractory to Chemotherapy: A Pilot Study II Enrolling Neuroendocrine Tumor CA
Safety and Efficacy of 68Ga-DOTA-tyr3-Octreotide PET/CT in Diagnosis, Staging and Measurement of Response to Treatment in Patients With Somatostatin Receptor Positive Tumors: Comparison to Octreoscan Plus High-Resolution, Contrast Enhanced CT. Enrolling
Carcinoid Tumor
Neuroendocrine Tumor
IA
Randomized Phase II Study of Everolimus Alone Versus Everolimus Plus Bevacizumab in Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors II Not Recruiting Pancreatic Neuroendocrine Tumor
AL
CA
CO
CT
DC
DE
FL
GA
HI
ID
IL
IN
IA
KS
KY
LA
MD
MA
MI
MN
MO
MT
NE
NH
NJ
NY
NC
ND
OH
OK
OR
PA
SC
SD
TN
TX
UT
VA
WA
WI
WY
Randomized Phase II Study of BEZ235 or Everolimus in Advanced Pancreatic Neuroendocrine Tumors II Enrolling Pancreatic Neuroendocrine Tumor
AZ
CA
CO
FL
IL
KY
NY
PA
TX
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754, IND 75648) Versus Placebo in Patients With Progressive Carcinoid Tumors II Enrolling
Carcinoid Tumor
Neuroendocrine Tumor
Pulmonary Carcinoid
CA
CO
FL
HI
IL
IA
LA
MI
MN
MS
NH
NC
OH
OK
OR
PA
SC
WI
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms Enrolling Neuroendocrine Tumor MD
Potential Imaging and Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors Enrolling Pancreatic Neuroendocrine Tumor NY
Pilot Study To Assess The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases Enrolling Neuroendocrine Tumor NY
Pilot Phase II Study of Targeted Radiotherapy With I-metaiodobenzylguanidine (I-MIBG) in Patients With Resistant Neuroblastoma or Malignant Chromaffin Cell Tumors II Enrolling Pheochromocytoma NY
Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients III Not Recruiting Neuroendocrine Tumor
AL
AK
AR
CA
CO
CT
DC
DE
FL
GA
ID
IL
IN
IA
KS
KY
LA
MD
MA
MI
MN
MS
MO
MT
NE
NV
NJ
NM
NY
NC
ND
OH
OK
OR
PA
SC
SD
TN
TX
VA
WA
WV
WI
WY
Phase II Study of Ziv-aflibercept in Patients With Advanced, Progressive Carcinoid Tumors II Enrolling
Carcinoid Tumor
Neuroendocrine Tumor
MA
Phase II Study of Pasireotide LAR in Patients With Metastatic Neuroendocrine Carcinomas II Not Recruiting
Carcinoid Tumor
Pancreatic Neuroendocrine Tumor
CA
FL
Phase II Study of Panitumumab in the Treatment of Carcinoid Syndrome II Carcinoid Tumor MA
Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes II Enrolling Neuroendocrine Tumor MD
Phase II Study of Above-Label Octreotide-LAR in Patients With Insufficiently Controlled Carcinoid Syndrome II Enrolling Carcinoid Tumor FL

Tell Your Story

Get the facts on pancreatic neuroendocrine cancer

Sign-up for our e-Newsletter.

Tell Your Story

video

Latest Video

Check out the CFCF video library.

Sign-up for our e-Newsletter.

Nancy

Ron's Blog

Read the latest blog from CFCF's Executive Director.

video

Latest Video

Check out the CFCF video library.

Lauren

Lauren's Blog

Read the latest blog from CFCF's Director of Research.

Nancy

Ron's Blog

Read the latest blog from CFCF's Executive Director.

Connect with CFCF online:
FacebookTwitterYouTube

Lauren

Lauren's Blog

Read the latest blog from CFCF's Director of Research.

Seal Exchange      

Connect with CFCF online:
FacebookTwitterYouTube

Seal Exchange